Rectal absorption and disposition of secobarbital in epileptic children. 1982

H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen

The absorption and disposition of rectally administered secobarbital was studied in ten epileptic children, ages 2-13 yrs. Five subjects received secobarbital rectally in solution, and the other five received secobarbital suppositories. Concentration of secobarbital in serum was serially determined during 48 hrs after a single rectal dose of about 5 mg/kg. The rate of absorption of secobarbital, as measured by the time to reach peak serum concentration, was much more rapid from the solution than the suppository (0.92 +/- 0.47 hr vs 4.60 +/ 2.30 hr). The peak serum concentration of secobarbital in the solution group was consistently higher than in the suppository group (2.26 +/- 0.37 micrograms/ml vs 1.35 +/- 0.24 microgram/ml). None of the individual peak serum concentrations exceeded 3 micrograms/ml, which is well below the previously reported minimum toxic concentration of secobarbital (ie, 6 microgram/ml). The elimination half-life of secobarbital varied over a wide range, from 2.7 to 13.5 hr, and is, on the average, shorter than estimates previously reported for adult volunteers or poly-drug abusers. Also, the mean elimination half-life did not differ between the solution and the suppository groups. The extent of rectal absorption of secobarbital, as assessed by the area under the serum concentration time curve, was not significantly different between the solution and the suppository treatments. If rectal secobarbital is considered for treatment of prolonged seizure, a rectal solution may offer a more rapid and consistent onset of action than with the suppository preparation.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D012007 Rectum The distal segment of the LARGE INTESTINE, between the SIGMOID COLON and the ANAL CANAL. Rectums
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012631 Secobarbital A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity. Meballymal,Quinalbarbitone,Sebar,Secobarbital Sodium,Seconal,Seconal Sodium,Sodium, Secobarbital

Related Publications

H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen
April 1982, Archives of disease in childhood,
H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen
April 1977, British journal of clinical pharmacology,
H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen
January 1974, Drug metabolism and disposition: the biological fate of chemicals,
H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen
August 1974, Clinical pharmacology and therapeutics,
H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen
January 1986, Revista chilena de pediatria,
H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen
September 1968, Canadian Anaesthetists' Society journal,
H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen
July 1974, Pediatrics,
H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen
September 1982, The International journal of pediatric nephrology,
H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen
June 1978, British journal of clinical pharmacology,
H L Levine, and M E Cohen, and P K Duffner, and D J Lacey, and R Karpynec, and D D Shen
August 1984, Journal of pharmaceutical sciences,
Copied contents to your clipboard!